AnaptysBio (NASDAQ:ANAB) Raised to “Strong-Buy” at UBS Group

AnaptysBio (NASDAQ:ANAB) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

ANAB has been the topic of several other research reports. Barclays cut their price target on AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Truist Financial increased their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Wall Street Zen raised shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Finally, Stifel Nicolaus reduced their price objective on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.40.

AnaptysBio Stock Down 3.1%

NASDAQ ANAB opened at $43.80 on Wednesday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -15.53 and a beta of 0.32. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $52.47. The stock has a fifty day simple moving average of $42.46 and a 200 day simple moving average of $31.30.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. The company had revenue of $76.32 million for the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. Research analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has authorized a stock repurchase program on Friday, November 21st that permits the company to buyback $100.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity at AnaptysBio

In related news, insider Paul F. Lizzul sold 2,235 shares of AnaptysBio stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total transaction of $100,820.85. Following the completion of the sale, the insider owned 37,213 shares of the company’s stock, valued at approximately $1,678,678.43. This trade represents a 5.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Dennis Mulroy sold 1,908 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $45.11, for a total transaction of $86,069.88. Following the completion of the transaction, the chief financial officer owned 17,667 shares in the company, valued at approximately $796,958.37. This trade represents a 9.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 112,624 shares of company stock worth $5,171,459 in the last ninety days. Insiders own 33.50% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently made changes to their positions in the business. HighMark Wealth Management LLC grew its stake in shares of AnaptysBio by 58.2% during the 2nd quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock valued at $3,231,000 after purchasing an additional 53,550 shares during the period. Panagora Asset Management Inc. bought a new position in shares of AnaptysBio in the 2nd quarter worth approximately $741,000. Allianz Asset Management GmbH purchased a new position in shares of AnaptysBio in the second quarter worth approximately $337,000. Los Angeles Capital Management LLC bought a new stake in AnaptysBio during the second quarter valued at approximately $334,000. Finally, Savant Capital LLC purchased a new stake in AnaptysBio during the second quarter valued at approximately $241,000.

AnaptysBio News Roundup

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Anaptys filed a partial motion to dismiss Tesaro (a GSK subsidiary)’s anticipatory breach claim in Delaware Chancery Court, which, if sustained, could reduce near‑term royalty exposure tied to Jemperli sales and lower legal risk. Reuters: AnaptysBio seeks partial dismissal GlobeNewswire: Motion to dismiss filing
• Positive Sentiment: Recent fundamentals and capital actions remain supportive: Anaptys reported an earnings and revenue beat in November and its board authorized up to $100M in share repurchases, which can support the share price over time by signaling management confidence and reducing outstanding float. MarketBeat ANAB coverage
• Neutral Sentiment: Upcoming event: CEO Daniel Faga will present at the J.P. Morgan Healthcare Conference (Jan. 13), which could catalyze new corporate updates or guidance but is unlikely to move the stock absent specific news. GlobeNewswire: JPM presentation
• Neutral Sentiment: Institutional positioning: Several funds have added or initiated positions recently, which can provide longer‑term demand but also increases the potential for large block trades to move the stock. MarketBeat ownership data
• Negative Sentiment: Insider selling: Multiple insiders (including the CEO and CFO) disclosed sizable sales on Jan. 5–7 that materially reduced their holdings; public Form 4 filings and media reports of these sales are likely contributing to today’s downward pressure as some investors view clustered insider sales negatively. InsiderTrades: insider selling alerts

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.